Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck, Pfizer Decorate Consumer Health 'For Sale' Signs With Strong Results

Executive Summary

Merck KGAA reports 11% growth in sales of its OTC lines over a year ago, but, like Pfizer, looks to sharpen its long-term focus on the Rx business.


Related Content

Reckitt Benckiser Gives Consumer Health Portfolio Its Own Home – What's Next?
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
Big Pharma Set To Compete For German Merck's Consumer Health Unit
GSK Trims Nutritional Drink Lines, Wants All Of Its Consumer JV Pie
Glaxo And Novartis Scratch Each Other’s Back With Consumer Product JV


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts